EGFR (C797S)

EGFR · Variant type: point · HGVS: p.C797S

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Canertinib	99.9%	0.1%	96.49
2	Gefitinib	99.7%	0.3%	99.25
3	Erlotinib	99.6%	0.4%	99.75
4	Dacomitinib	99.5%	0.6%	97.99
5	Neratinib	99.3%	0.7%	93.18
6	Afatinib	99.2%	0.8%	98.50
7	Bosutinib	99.2%	0.8%	87.22
8	Vandetanib	99.2%	0.8%	95.74
9	Lapatinib	99.1%	0.9%	99.25
10	Fostamatinib	98.7%	1.3%	96.74
11	Brigatinib	97.1%	2.9%	82.96
12	Dasatinib	96.2%	3.8%	87.97
13	Defactinib	94.3%	5.7%	92.68
14	Ponatinib	89.3%	10.7%	78.23
15	Pacritinib	87.9%	12.1%	88.64
16	Mobocertinib	86.6%	13.4%	97.22
17	Pirtobrutinib	83.8%	16.2%	99.49
18	Gilteritinib	80.2%	19.8%	88.97
19	Alectinib	78.9%	21.1%	95.49
20	Ibrutinib	73.2%	26.8%	94.74
21	Trametinib	66.4%	33.6%	99.50
22	Imatinib	64.4%	35.6%	99.00
23	Dabrafenib	60.6%	39.4%	94.74
24	Fedratinib	58.3%	41.7%	96.21
25	Lorlatinib	57.7%	42.3%	97.24

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Canertinib	99.9%	98.4%	+1.4%
Gefitinib	99.7%	99.9%	-0.2%
Erlotinib	99.6%	99.4%	+0.1%
Dacomitinib	99.5%	99.8%	-0.3%
Neratinib	99.3%	100.0%	-0.7%
Afatinib	99.2%	100.0%	-0.8%
Bosutinib	99.2%	99.3%	-0.1%
Vandetanib	99.2%	99.3%	-0.2%
Lapatinib	99.1%	99.2%	-0.0%
Fostamatinib	98.7%	97.8%	+1.0%
Brigatinib	97.1%	98.5%	-1.3%
Dasatinib	96.2%	97.9%	-1.7%
Defactinib	94.3%	94.6%	-0.2%
Ponatinib	89.3%	—	—
Pacritinib	87.9%	—	—
Mobocertinib	86.6%	100.0%	-13.4%
Pirtobrutinib	83.8%	—	—
Gilteritinib	80.2%	91.0%	-10.8%
Alectinib	78.9%	—	—
Ibrutinib	73.2%	99.3%	-26.2%
Trametinib	66.4%	—	—
Imatinib	64.4%	—	—
Dabrafenib	60.6%	—	—
Fedratinib	58.3%	—	—
Lorlatinib	57.7%	—	—

Cancer	Organ	Source
carcinoma_lung	Lung	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 37.2ms